Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Inactivation of SARS-CoV-2 and HCoV-229E in vitro by ColdZyme® a medical device mouth spray against the common cold

Gudmundsdottir, Ágústa ; Scheving, Reynir ; Lindberg, Fredrik and Stefansson, Bjarki (2021) In Journal of Medical Virology 93(3). p.1792-1795
Abstract

Background: The coronavirus disease 2019 (COVID-19) pandemic calls for effective and safe treatments. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 actively replicates in the throat, unlike SARS-CoV, and shows high pharyngeal viral shedding even in patients with mild symptoms of the disease. HCoV-229E is one of four coronaviruses causing the common cold. In this study, the efficacy of ColdZyme® (CZ-MD), a medical device mouth spray, was tested against SARS-CoV-2 and HCoV-229E in vitro. The CZ-MD provides a protective glycerol barrier containing cod trypsin as an ancillary component. Combined, these ingredients can inactivate common cold viruses in the throat and mouth. The CZ-MD is believed to act on the... (More)

Background: The coronavirus disease 2019 (COVID-19) pandemic calls for effective and safe treatments. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 actively replicates in the throat, unlike SARS-CoV, and shows high pharyngeal viral shedding even in patients with mild symptoms of the disease. HCoV-229E is one of four coronaviruses causing the common cold. In this study, the efficacy of ColdZyme® (CZ-MD), a medical device mouth spray, was tested against SARS-CoV-2 and HCoV-229E in vitro. The CZ-MD provides a protective glycerol barrier containing cod trypsin as an ancillary component. Combined, these ingredients can inactivate common cold viruses in the throat and mouth. The CZ-MD is believed to act on the viral surface proteins that would perturb their entry pathway into cells. The efficacy and safety of the CZ-MD have been demonstrated in clinical trials on the common cold. Method of Study: The ability of the CZ-MD to inactivate SARS-CoV-2 and HCoV-229E was tested using an in vitro virucidal suspension test (ASTM E1052). Results: CZ-MD inactivated SARS-CoV-2 by 98.3% and HCoV-229E by 99.9%. Conclusion: CZ-MD mouth spray can inactivate the respiratory coronaviruses SARS-CoV-2 and HCoV-229E in vitro. Although the in vitro results presented cannot be directly translated into clinical efficacy, the study indicates that CZ-MD might offer a protective barrier against SARS-CoV-2 and a decreased risk of COVID-19 transmission.

(Less)
Please use this url to cite or link to this publication:
author
; ; and
publishing date
type
Contribution to journal
publication status
published
subject
keywords
cell cultures, coronavirus, microbial cultures, respiratory tract
in
Journal of Medical Virology
volume
93
issue
3
pages
1792 - 1795
publisher
John Wiley & Sons Inc.
external identifiers
  • scopus:85092480286
  • pmid:32975843
ISSN
0146-6615
DOI
10.1002/jmv.26554
language
English
LU publication?
no
id
6e09b300-ad55-431e-842b-aa9ccddd8dcf
date added to LUP
2021-01-08 13:13:24
date last changed
2024-09-19 13:05:35
@article{6e09b300-ad55-431e-842b-aa9ccddd8dcf,
  abstract     = {{<p>Background: The coronavirus disease 2019 (COVID-19) pandemic calls for effective and safe treatments. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 actively replicates in the throat, unlike SARS-CoV, and shows high pharyngeal viral shedding even in patients with mild symptoms of the disease. HCoV-229E is one of four coronaviruses causing the common cold. In this study, the efficacy of ColdZyme® (CZ-MD), a medical device mouth spray, was tested against SARS-CoV-2 and HCoV-229E in vitro. The CZ-MD provides a protective glycerol barrier containing cod trypsin as an ancillary component. Combined, these ingredients can inactivate common cold viruses in the throat and mouth. The CZ-MD is believed to act on the viral surface proteins that would perturb their entry pathway into cells. The efficacy and safety of the CZ-MD have been demonstrated in clinical trials on the common cold. Method of Study: The ability of the CZ-MD to inactivate SARS-CoV-2 and HCoV-229E was tested using an in vitro virucidal suspension test (ASTM E1052). Results: CZ-MD inactivated SARS-CoV-2 by 98.3% and HCoV-229E by 99.9%. Conclusion: CZ-MD mouth spray can inactivate the respiratory coronaviruses SARS-CoV-2 and HCoV-229E in vitro. Although the in vitro results presented cannot be directly translated into clinical efficacy, the study indicates that CZ-MD might offer a protective barrier against SARS-CoV-2 and a decreased risk of COVID-19 transmission.</p>}},
  author       = {{Gudmundsdottir, Ágústa and Scheving, Reynir and Lindberg, Fredrik and Stefansson, Bjarki}},
  issn         = {{0146-6615}},
  keywords     = {{cell cultures; coronavirus; microbial cultures; respiratory tract}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{1792--1795}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{Journal of Medical Virology}},
  title        = {{Inactivation of SARS-CoV-2 and HCoV-229E in vitro by ColdZyme® a medical device mouth spray against the common cold}},
  url          = {{http://dx.doi.org/10.1002/jmv.26554}},
  doi          = {{10.1002/jmv.26554}},
  volume       = {{93}},
  year         = {{2021}},
}